U.S. markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.32
    -0.04 (-0.08%)
     
  • Gold

    1,836.40
    +6.50 (+0.36%)
     
  • Silver

    25.03
    +0.17 (+0.68%)
     
  • EUR/USD

    1.2083
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • GBP/USD

    1.3585
    +0.0002 (+0.01%)
     
  • USD/JPY

    103.6910
    -0.1090 (-0.11%)
     
  • BTC-USD

    36,685.43
    +36,685.43 (+0.00%)
     
  • CMC Crypto 200

    708.54
    -26.60 (-3.62%)
     
  • FTSE 100

    6,720.65
    -15.06 (-0.22%)
     
  • Nikkei 225

    28,242.21
    0.00 (0.00%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Mesoblast Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 7, 2020 - MESO

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - November 11, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Mesoblast Limited ("Mesoblast") (NASDAQ: MESO) between April 16, 2019 and October 1, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Southern District of New York. To get more information go to:

https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=10856&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you suffered a loss in Mesoblast you have until December 7, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67963